{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:37:23Z","timestamp":1768001843517,"version":"3.49.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The addition of clarithromycin enhances the efficacy of lenalidomide plus dexamethasone in treatment-naive multiple myeloma (MM). We conducted a phase 2 trial to evaluate the safety and efficacy of clarithromycin, pomalidomide, and dexamethasone (ClaPd) in relapsed or refractory multiple myeloma (RRMM) with prior lenalidomide exposure. One hundred twenty patients with a median of 5 prior lines of therapy received clarithromycin 500 mg orally twice daily, pomalidomide 4 mg orally on days 1 to 21, and dexamethasone 40 mg orally on days 1, 8, 15, and 22 of a 28-day cycle. The overall response rate (ORR) was 60% with 23% achieving at least a very good partial response. There was no statistical difference in response rates for patients who were refractory to lenalidomide (ORR, 58%), bortezomib (ORR, 55%), or both lenalidomide and bortezomib (ORR, 54%). Median progression-free survival (PFS) for the cohort was 7.7 months and median overall survival (OS) was 19.2 months. A history of dual-refractoriness to lenalidomide and bortezomib did not significantly impact either PFS or OS. The most common toxicities were neutropenia (83%), lymphopenia (74%), and thrombocytopenia (71%). The most common grade \u22653 toxicities included neutropenia (58%), thrombocytopenia (31%), and anemia (28%). ClaPd is an effective combination in RRMM with response and survival outcomes that are independent of lenalidomide- or bortezomib-refractory status. Toxicities are manageable with low rates of nonhematologic or high-grade events. ClaPd is a convenient, all-oral option in RRMM with comparable efficacy to other highly active, 3-drug, pomalidomide-based combinations. This trial was registered at www.clinicaltrials.gov as #NCT01159574.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018028027","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T16:55:27Z","timestamp":1550768127000},"page":"603-611","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma"],"prefix":"10.1182","volume":"3","author":[{"given":"Tomer M.","family":"Mark","sequence":"first","affiliation":[{"name":"Blood Cancer and BMT Program, Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Forsberg","sequence":"additional","affiliation":[{"name":"Blood Cancer and BMT Program, Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana C.","family":"Rossi","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger N.","family":"Pearse","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen A.","family":"Pekle","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Perry","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelique","family":"Boyer","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Tegnestam","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jayabalan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morton","family":"Coleman","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"issue":"5","key":"2020021108323254900_B1","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2020021108323254900_B2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40265-013-0047-x","article-title":"Pomalidomide: first global approval","volume":"73","author":"Elkinson","year":"2013","journal-title":"Drugs"},{"issue":"11","key":"2020021108323254900_B3","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"2020021108323254900_B4","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"issue":"19","key":"2020021108323254900_B5","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"2020021108323254900_B6","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2020021108323254900_B7","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2020021108323254900_B8","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41375-018-0038-8","article-title":"Phase I\/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"32","author":"Krishnan","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"2020021108323254900_B9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000438855","article-title":"Clarithromycin synergistically enhances thalidomide cytotoxicity in myeloma cells","volume":"135","author":"Qiu","year":"2016","journal-title":"Acta Haematol"},{"issue":"2","key":"2020021108323254900_B10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0924-8579(98)00091-0","article-title":"Effect of clarithromycin and azithromycin on production of cytokines by human monocytes","volume":"11","author":"Khan","year":"1999","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"2020021108323254900_B11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijantimicag.2003.07.006","article-title":"Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophils","volume":"23","author":"Reato","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"2020021108323254900_B12","first-page":"5S","article-title":"Clinical implications of the immunomodulatory effects of macrolides","volume":"117","author":"Tamaoki","year":"2004","journal-title":"Am J Med"},{"issue":"4","key":"2020021108323254900_B13","first-page":"815","article-title":"Clarithromycin attenuates autophagy in myeloma cells","volume":"37","author":"Nakamura","year":"2010","journal-title":"Int J Oncol"},{"issue":"6","key":"2020021108323254900_B14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0091-6749(99)70175-2","article-title":"Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy","volume":"103","author":"Fost","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2020021108323254900_B15","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0093-7754(01)90033-8","article-title":"Novel therapies targeting the myeloma cell and its bone marrow microenvironment","volume":"28","author":"Hideshima","year":"2001","journal-title":"Semin Oncol"},{"issue":"3","key":"2020021108323254900_B16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2249.1996.46752.x","article-title":"Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells","volume":"104","author":"Matsuoka","year":"1996","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"2020021108323254900_B17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2007-05-090258","article-title":"BiRD (Biaxin [clarithromycin]\/Revlimid [lenalidomide]\/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma","volume":"111","author":"Niesvizky","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2020021108323254900_B18","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1182\/blood-2012-08-448563","article-title":"BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"issue":"18","key":"2020021108323254900_B19","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2020021108323254900_B20","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"2020021108323254900_B21","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.clml.2017.09.010","article-title":"Cellular proliferation by multiplex immunohistochemistry identifies high-risk multiple myeloma in newly diagnosed, treatment-naive patients","volume":"17","author":"Ely","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2020021108323254900_B22","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","article-title":"Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du My\u00e9lome 2009-02","volume":"121","author":"Leleu","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2020021108323254900_B23","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020021108323254900_B24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2020021108323254900_B25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ajh.21777","article-title":"Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma","volume":"85","author":"Gay","year":"2010","journal-title":"Am J Hematol"},{"issue":"11","key":"2020021108323254900_B26","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"2020021108323254900_B27","first-page":"746","article-title":"Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides","volume":"250","author":"Tinel","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"2020021108323254900_B28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0006-2952(97)00166-4","article-title":"In vitro metabolism of dexamethasone (DEX) in human liver and kidney: the involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies","volume":"54","author":"Tomlinson","year":"1997","journal-title":"Biochem Pharmacol"},{"issue":"24","key":"2020021108323254900_B29","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2020021108323254900_B30","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3324\/haematol.2015.125864","article-title":"Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed\/refractory multiple myeloma","volume":"100","author":"San Miguel","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2020021108323254900_B31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40164-018-0110-0","article-title":"A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma","volume":"7","author":"Gregersen","year":"2018","journal-title":"Exp Hematol Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/4\/603\/1631120\/advances028027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/4\/603\/1631120\/advances028027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T08:59:22Z","timestamp":1581411562000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/4\/603\/246748\/Phase-2-study-of-clarithromycin-pomalidomide-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,2,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018028027","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,21]]}}}